Streptokinase is an efficient thrombolytic agent used to treat thromboembolic disorders.
Conventional streptokinase formulations have limited thrombolytic activity and several …

Streptokinase is one of the most commonly used thrombolytic agents for the treatment of
thromboembolism. Short half-life of the streptokinase requires administration of higher dose …

To prolong the biological half-life of streptokinase, a thrombolytic agent, streptokinase-
bearing liposome with and distearolyphosphatidyl ethanolamine-N-poly (ethylene glycol) …

Acute thrombosis has a narrow therapeutic window and remains the leading cause of
morbidity and mortality, while thrombolytic therapy has limited efficacy and risk of side …

The use of streptokinase (SK) in the clinic is limited by the lack of fibrin-specificity and the
short half-life of the drug. We have developed a new dosage form of streptokinase …

Streptokinase (SK) is an effective thrombolytic agent, but it has a short half-life due to its
rapid elimination from the body. In this study, we prepared and evaluated polyethyleneglycol …

In recent times, search for potent and highly selective thrombolytic agents with minimal side
effects has become a major area of research. The aim of the present study was to develop …

Streptokinase is being successfully used as a thrombolytic agent for restoring the blood flow
following thromboembolism and myocardial infarction. However, high immunogenicity of the …

The successful design of new thrombolytic agents depends on providing these agents with
increased clot selectivity. As recently demonstrated (10), entrapment of tissue plasminogen …

The present study was aimed to study the effect of RGD peptide conjugation on the bio-
distribution behaviour of long circulatory liposomes in the thrombosed rat model. Further …